I agree the comparison between IBM and Abott may not be the best, but my point is, the industry giants do not always make the best decisions. I've often wondered if Abbott licensed Recaf simply to delay it from going to market and to buy time until something better was developed. Abbott already generates plenty of revenue with PSA. How much more can they make above the current revenues fromPSA test by using Recaf. Currently in my opinion, the only benefit to Abbott is accuracy. As Gold pointed out before, Abbott wanted a test that was 100% accurate, with no false positives.

JMHO